Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
The family of lipid kinases termed phosphoinositide-3-kinase (PI3K) is known to contribute at multiple levels to innate and adaptive immune responses, and is hence an attractive target for drug discovery in inflammatory and autoimmune disease, including respiratory diseases. The development of isoform-selective pharmacological inhibitors, targeted gene manipulation and short interfering RNA (siRNA) target validation have facilitated a better understanding of the role that each member of this family of kinases plays in the physiology and pathology of the respiratory system. In this review, we will evaluate the evidence for the roles of specific PI3K isoforms in the lung and airways, and discuss their potential as targets for novel drug therapies.
Medina-Tato
David A
DA
Department of Pharmacy & Pharmacology, University of Bath, Bath, UK.
Ward
Stephen G
SG
Watson
Malcolm L
ML
D001249:Asthma / Q000276:immunology; D006801:Humans; D007962:Leukocytes / Q000201:enzymology*; D008171:Lung Diseases / Q000276:immunology*; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology*; D020033:Protein Isoforms / Q000276:immunology; D029424:Pulmonary Disease, Chronic Obstructive / Q000276:immunology; D012128:Respiratory Distress Syndrome / Q000276:immunology; D015398:Signal Transduction / Q000276:immunology
D019869:Phosphatidylinositol 3-Kinases; D020033:Protein Isoforms